Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALLISTO
NCT06681324Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AZD7798 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events at Week 12, Number of participants with abnormal Vital signs: Blood pressure at Week 12 and 10 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06681324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681324.